This study focuses on various types of solid tumors that have a specific characteristic called FGFR2b overexpression. The types of cancer being studied include head and neck squamous cell carcinoma, triple-negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, ovarian epithelial carcinoma, endometrial adenocarcinoma, and cervical carcinoma. The treatment being tested is a medicine called bemarituzumab (also known as AMG 552), which is given through an intravenous infusion directly into the bloodstream.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.